Patents by Inventor Nathan David Pfeifer

Nathan David Pfeifer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEMORY MODULE GUIDANCE AND RETENTION STRUCTURE
    Publication number: 20240097365
    Abstract: An apparatus for guidance and retention of integrated circuit boards includes a first structure configured to receive a first integrated circuit board and guide the first integrated circuit board for coupling to a substrate. The apparatus further includes a second structure configured to be removably coupled to the first structure. The second structure includes a first spring member configured to apply a first compressive force to the first integrated circuit board.
    Type: Application
    Filed: September 16, 2022
    Publication date: March 21, 2024
    Inventors: NATHAN LEE DUNFEE, KEVIN O'CONNELL, CHRISTOPHER M. MARROQUIN, STEPHEN P. MROZ, MARK DAVID PFEIFER, KENNETH E. LUBAHN, JUSTIN CHRISTOPHER ROGERS
  • METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L
    Publication number: 20230021647
    Abstract: Provided herein are methods of treating a patient infected with a coronavirus and having a baseline level of CRP below 150 mg/L, comprising administering to the patient a compound of formula 1: or a pharmaceutically-acceptable salt thereof.
    Type: Application
    Filed: June 20, 2022
    Publication date: January 26, 2023
    Inventors: Rajeev Saggar, Tuan Stevon Nguyen, David A. Lombardi, Glenn D. Crater, Edmund J. Moran, Nathan David Pfeifer, Wayne Arthur Yates, Kyla Dee-Kinnick Kennedy, Joseph Budman, Arthur Lo
  • Method of treating a patient infected with a coronavirus with a dimethyl amino azetidine amide compound
    Publication number: 20210346357
    Abstract: Provided herein are methods of treating a patient infected with a coronavirus comprising administering to the patient a compound of formula 1: or a pharmaceutically-acceptable salt thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: November 11, 2021
    Applicant: Theravance Biopharma R&D IP, LLC
    Inventors: Glenn Douglas Crater, Edmund J. Moran, Rajeev Saggar, Nathan David Pfeifer, Wayne Arthur Yates, Kyla Dee-Kinnick Kennedy, Joseph Budman, Arthur Lo